157 related articles for article (PubMed ID: 25702159)
1. Targeted Immunotherapy Designed to Treat MUC1-Expressing Solid Tumour.
Acres B; Lacoste G; Limacher JM
Curr Top Microbiol Immunol; 2017; 405():79-97. PubMed ID: 25702159
[TBL] [Abstract][Full Text] [Related]
2. MUC1 as a target antigen for cancer immunotherapy.
Acres B; Limacher JM
Expert Rev Vaccines; 2005 Aug; 4(4):493-502. PubMed ID: 16117706
[TBL] [Abstract][Full Text] [Related]
3. MUC1 immunotherapy.
Beatson RE; Taylor-Papadimitriou J; Burchell JM
Immunotherapy; 2010 May; 2(3):305-27. PubMed ID: 20635898
[TBL] [Abstract][Full Text] [Related]
4. Enhanced induction of anti-tumor CTLs in vitro by a lentivirus-transduced dendritic cell vaccine expressing secondary lymphoid tissue chemokine and mucin 1.
Wang B; Zhu Y; Zhang JJ; Chen Z; Liang WB; Xu ZK
Asian Pac J Cancer Prev; 2011; 12(11):2811-7. PubMed ID: 22393946
[TBL] [Abstract][Full Text] [Related]
5. Update on Mucin-1 immunotherapy in cancer: a clinical perspective.
Rivalland G; Loveland B; Mitchell P
Expert Opin Biol Ther; 2015; 15(12):1773-87. PubMed ID: 26453294
[TBL] [Abstract][Full Text] [Related]
6. Tecemotide: an antigen-specific cancer immunotherapy.
Wurz GT; Kao CJ; Wolf M; DeGregorio MW
Hum Vaccin Immunother; 2014; 10(11):3383-93. PubMed ID: 25483673
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells.
Chen D; Xia J; Tanaka Y; Chen H; Koido S; Wernet O; Mukherjee P; Gendler SJ; Kufe D; Gong J
Immunology; 2003 Jun; 109(2):300-7. PubMed ID: 12757626
[TBL] [Abstract][Full Text] [Related]
8. MUC1-based recombinant Bacillus Calmette-Guerin vaccines as candidates for breast cancer immunotherapy.
Yuan S; Shi C; Liu L; Han W
Expert Opin Biol Ther; 2010 Jul; 10(7):1037-48. PubMed ID: 20420512
[TBL] [Abstract][Full Text] [Related]
9. Advances of MUC1 as a target for breast cancer immunotherapy.
Yang E; Hu XF; Xing PX
Histol Histopathol; 2007 Aug; 22(8):905-22. PubMed ID: 17503348
[TBL] [Abstract][Full Text] [Related]
10. MUC1 immunotherapy is here to stay.
Kimura T; Finn OJ
Expert Opin Biol Ther; 2013 Jan; 13(1):35-49. PubMed ID: 22998452
[TBL] [Abstract][Full Text] [Related]
11. Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer.
Scheid E; Major P; Bergeron A; Finn OJ; Salter RD; Eady R; Yassine-Diab B; Favre D; Peretz Y; Landry C; Hotte S; Mukherjee SD; Dekaban GA; Fink C; Foster PJ; Gaudet J; Gariepy J; Sekaly RP; Lacombe L; Fradet Y; Foley R
Cancer Immunol Res; 2016 Oct; 4(10):881-892. PubMed ID: 27604597
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell vaccine immunotherapy of cancer targeting MUC1 mucin.
Kontani K; Taguchi O; Ozaki Y; Hanaoka J; Sawai S; Inoue S; Abe H; Hanasawa K; Fujino S
Int J Mol Med; 2003 Oct; 12(4):493-502. PubMed ID: 12964025
[TBL] [Abstract][Full Text] [Related]
13. ImMucin: a novel therapeutic vaccine with promiscuous MHC binding for the treatment of MUC1-expressing tumors.
Kovjazin R; Volovitz I; Kundel Y; Rosenbaum E; Medalia G; Horn G; Smorodinsky NI; Brenner B; Carmon L
Vaccine; 2011 Jun; 29(29-30):4676-86. PubMed ID: 21570434
[TBL] [Abstract][Full Text] [Related]
14. Mannan-MUC1-pulsed dendritic cell immunotherapy: a phase I trial in patients with adenocarcinoma.
Loveland BE; Zhao A; White S; Gan H; Hamilton K; Xing PX; Pietersz GA; Apostolopoulos V; Vaughan H; Karanikas V; Kyriakou P; McKenzie IF; Mitchell PL
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):869-77. PubMed ID: 16467101
[TBL] [Abstract][Full Text] [Related]
15. [Prediction of WT1/MUC1 peptide dendritic cell therapy responders by quantification of ex vivo induced mRNA in whole blood].
Kato Y; Mitsuhashi M
Gan To Kagaku Ryoho; 2012 Nov; 39(12):1803-5. PubMed ID: 23267892
[TBL] [Abstract][Full Text] [Related]
16. Heat shock fusion protein induces both specific and nonspecific anti-tumor immunity.
Li D; Li H; Zhang P; Wu X; Wei H; Wang L; Wan M; Deng P; Zhang Y; Wang J; Liu Y; Yu Y; Wang L
Eur J Immunol; 2006 May; 36(5):1324-36. PubMed ID: 16619287
[TBL] [Abstract][Full Text] [Related]
17. MUC1 and breast cancer.
Apostolopoulos V; Pietersz GA; McKenzie IF
Curr Opin Mol Ther; 1999 Feb; 1(1):98-103. PubMed ID: 11249691
[TBL] [Abstract][Full Text] [Related]
18. Increased immunogenicity of tumor-associated antigen, mucin 1, engineered to express alpha-gal epitopes: a novel approach to immunotherapy in pancreatic cancer.
Deguchi T; Tanemura M; Miyoshi E; Nagano H; Machida T; Ohmura Y; Kobayashi S; Marubashi S; Eguchi H; Takeda Y; Ito T; Mori M; Doki Y; Sawa Y
Cancer Res; 2010 Jul; 70(13):5259-69. PubMed ID: 20530670
[TBL] [Abstract][Full Text] [Related]
19. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer.
Rochlitz C; Figlin R; Squiban P; Salzberg M; Pless M; Herrmann R; Tartour E; Zhao Y; Bizouarne N; Baudin M; Acres B
J Gene Med; 2003 Aug; 5(8):690-9. PubMed ID: 12898638
[TBL] [Abstract][Full Text] [Related]
20. Cancer immunotherapy: phase II clinical studies with TG4010 (MVA-MUC1-IL2).
Acres B
J BUON; 2007 Sep; 12 Suppl 1():S71-5. PubMed ID: 17935281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]